Spectral AI Q2 2026: Cash Burn Accelerates, Material Weakness Persists Despite FDA Win
MDAI sits 38% above its 52-week low of $1.18 on light trading volume (0.4× avg).
Summary
Spectral AI's Q2 2026 shows accelerating cash burn, declining revenue, and a persistent material weakness in financial controls, even as it prepares to launch its FDA-cleared DeepView System.
Key Events · Earnings and Guidance · MDAI
-
Revenue Plunges 36%
H1 2026 research and development revenue fell to $7.5 million from $11.8 million in H1 2025, driven by reduced BARDA reimbursements after FDA De Novo clearance and cost-share provisions on follow-on development.
-
Cash Burn Accelerates
Net cash used in operations was $7.8 million in H1 2026, up from $4.9 million in H1 2025. Cash and equivalents dropped to $14.0 million from $15.4 million at year-end 2025.
-
Material Weakness Unresolved
Management concluded disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness in internal control over financial reporting. Remediation efforts are ongoing but not yet validated.
-
Debt Increases with Second Avenue Tranche
On June 18, 2026, the company drew down the second $6.5 million tranche of its Avenue Capital financing, bringing total debt outstanding to $14.9 million. The interest-only period was extended to 24 months.
Analysis · MDAI · Industrial Applications And Services
Spectral AI's Q2 2026 report reveals a deteriorating financial position. Revenue fell 36% year-over-year as BARDA reimbursements wound down post-FDA authorization, while operating costs rose. The company burned $7.8 million in cash from operations in H1, leaving only $14.0 million in the bank. Management states this is sufficient for at least 12 months, but that assumes continued BARDA funding and access to the dilutive Yorkville SEPA. The material weakness in internal controls remains unremediated, and the company's auditor has not yet attested to its fix. The subsequent withdrawal of a subsidiary's IPO registration removes a potential non-dilutive funding source. Against the backdrop of a recent FDA De Novo clearance and a new Chief Commercial Officer, the financial strain raises questions about the company's ability to fund its commercial launch without further dilutive financing.
At the time of this filing, MDAI was trading at $1.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $54.4M. The 52-week trading range was $1.18 to $2.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.